Top Medical News

CGRP Antagonist Atogepant Improves Patient-Reported Outcomes as Migraine Preventive

November 29, 2022

By Marco Meglio

In a post-hoc analysis of the ADVANCE trial, atogepant 30 and 60 mg produced significant improvements in outcomes on Migraine-Specific Quality of Life Questionnaire and Activity Impairment in Migraine-Diary domains.

Using Nonpharmacological Interventions to Promote Healthier Lifestyles in Multiple Sclerosis

November 29, 2022

By Isabella Ciccone, MPH

Michelle Chen, PhD, neuropsychologist at Rutgers University, spoke about her current research grant on the longitudinal impact of health and lifestyle behaviors on cognition with MS.

AXS-05 Meets Primary End Point in Phase 3 Trial of Alzheimer Agitation

November 29, 2022

By Marco Meglio

Treatment with the investigational agent resulted in improvements in Alzheimer disease agitation, as well as significant delays in time to relapse and prevention of relapse.

Insomnia Diagnosis During Pregnancy Increased in the United States, Analysis Shows

November 28, 2022

By Isabella Ciccone, MPH

A recent cross-sectional analysis showed an increase in coded diagnoses of insomnia during pregnancy in the United States over time.

Although Increased, Risk of Epilepsy and Seizures Following COVID-19 Remain Low

November 28, 2022

By Marco Meglio

The relative risk of epilepsy or seizures after COVID-19 infection, compared with influenza infection, was more marked amongst children and non-hospitalized individuals over the 6-month time horizon.

Featured

Latest Videos

Insomnia Treatment Selection: DORA

S1P Receptor Modulator Treatment in Female Patients with MS

Comparing Reactive Microglia and Astrocytes in Secondary Progressive Multiple Sclerosis

Overview of Sphingosine 1-Phosphate (S1P) Receptor Modulators

Expanding the Capabilities of Treating Neuromuscular Poststroke Symptoms: Wayne Feng, MD, FAHA

Changing the Way Multiple Sclerosis Disease Progression is Perceived: Ruth Ann Marrie, MD, PhD, FRCPC

Expanding Neuropalliative Care to New Disease States: Benzi Kluger, MD, MS

Aquatic Therapy Improves MS Fatigue, MS Disease Pathology Not Defined by Courses, Rituximab Shows Positive Effect in Myasthenia Gravis

CBT as an Effective Mood Therapy for Patients with MS Experiencing Fatigue: Federica Picariello, PhD

Importance of Early Diagnosis of Sleep Disorders

Future Thoughts on Improving MS Trial Design, Calculations: Carrie Hersh, DO, MSc

Physical Movement Improves Fatigue for Patients with MS: Federica Picariello, PhD

Differences Between MS Patient Characteristics in Clinical Trials and Real-World Populations

Most Recent

This Week on NeurologyLive® — November 28, 2022

November 28, 2022

Article

Here's some of what is coming soon to NeurologyLive® this week.

Prioritizing Cognition and Adapting to Novel Therapeutics in Multiple Sclerosis

November 27, 2022

Article

Experts in neurology discuss changes in cognitive health and the role that sphingosine-1-phospate receptor modulators and disease-modifying therapies play in MS management.

NeurologyLive® Brain Games: November 27, 2022

November 27, 2022

Article

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

Treating NMOSD Early in the Disease Course: Inebilizumab’s Efficacy in N-MOmentum

November 26, 2022

Article

Bruce Cree, MD, PhD, MAS, FAAN, offered his perspective on data from the phase 2/3 N-MOmentum trial of the recently approved inebilizumab (Uplizna; Horizon Therapeutics) and why the therapy stands out from other NMOSD treatments.

NeurologyLive® Friday 5 — November 25, 2022

November 25, 2022

Article

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 25, 2022.

Cognition Issues in Multiple Sclerosis Are Vital to Address

November 25, 2022

Article

Cognitive problems have been reported to occur in as many as 7 in 10 individuals with MS, yet they remain a difficult and undertreated challenge in clinical care.

Digital Cognitive Behavioral Therapy Significantly Improves Insomnia Symptoms

November 24, 2022

Article

Nearly 40% of patients treated with CBT-I met the Athens Insomnia Score criteria for remission after 8 weeks of treatment compared with slightly above 10% of those on sham.

Furthering MS Treatment Selection: A Comparative Study of Peginterferon Beta-1a vs Interferon Beta-1a

November 24, 2022

Article

Peginterferon beta-1a, a pegylated form of interferon designed to maintain biologic effects in the body for longer periods, is being evaluated against CinnaGen’s interferon beta-1a formulation, CinnoVex.

The Relationship Between Epstein-Barr Virus and Multiple Sclerosis

November 23, 2022

Article

The paradigm-shifting evidence of the link between MS and EBV does not exist in isolation. In fact, the relationship has been suspected for more than 40 years, and evidence therein has been accumulating over the past 2 decades.

Severe COVID-19 Could Potentially Lead to Obstructive Sleep Apnea

November 23, 2022

Article

In a bidirectional Mendelian randomization analysis, findings revealed an association with obstructive sleep apnea and severe COVID-19 that were suggestive of a causal relationship.

Latest SAP Content

CGRP Antagonist Atogepant Improves Patient-Reported Outcomes as Migraine Preventive

Using Nonpharmacological Interventions to Promote Healthier Lifestyles in Multiple Sclerosis

Changing the Way Multiple Sclerosis Disease Progression is Perceived: Ruth Ann Marrie, MD, PhD, FRCPC

Expanding Neuropalliative Care to New Disease States: Benzi Kluger, MD, MS

View More SAP Content